Revlimid lenalidomide regulatory update

Switzerland approved Revlimid lenalidomide from Celgene to treat relapsed or refractory mantle cell lymphoma (MCL) after prior therapy with bortezomib and chemotherapy or rituximab. The thalidomide an...